Biontech Se  (BNTX)

Observing the fourth quarter of 2022 effort, the Biotechnology & Pharmaceuticals company's had top-line remained unaltered

BNTX reported fourth quarter of 2022 operating shortfall of $0 million

Published Mar 28 2023
Goran Soko / CSIMarket.com Contributer

pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_CommonsFor the most recent fiscal period BNTX reached balanced books of $0.00 per share compare to $0.00 a year prior and from $0.00 per share from the preceding reporting season.

The revenue remained unchanged to $0.00 million from $0.00 million in the comparable reporting season a year prior and sequentially from $0.00 million.

Net income of $10,566.528 million in the most recent fiscal period fell by -8.34 % from $11,527.600 million in the corresponding period a year before.

the Biotechnology & Pharmaceuticals company reported deficit of $10.57 billion and revenue of $0.00 million in the fiscal period 2022.

Biontech Se reported further balanced books in proportion to $0.00 in the preceding fiscal year, while by 0 % from $0.00 million a year prior.

Biontech Se is expected to report next financial results on March 26, 2024.

Biontech Se's Price to Book ratio

Biontech Se's Price to earnings ratio PE

Other BNTX's Earnings Reports

Other BNTX's Earnings Reports


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071